News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

How Drug Price Pressure Helped Sink Novo Nordisk A/S (NVO)'s Insulin Pill



11/17/2016 7:30:05 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Commercial rather than technical hurdles ultimately torpedoed Novo Nordisk's (NOVOb.CO) bid to make an oral form of insulin, its chief executive said on Wednesday, underscoring the impact of U.S. price pressure on the world's top insulin supplier.

An insulin pill, saving diabetics from daily injections, has long been seen as the "holy grail" of diabetes care, yet the Danish group announced last month it was throwing in the towel after several years of work.

"We actually made a phenomenal scientific achievement in demonstrating to ourselves it is possible to have an insulin tablet," Chief Executive Lars Rebien Sorensen told an industry conference.

Read at Reuters


comments powered by Disqus
Reuters
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES